Article Text

Download PDFPDF

Viewpoint
Costs of drugs for treatment of rheumatic diseases
  1. Rene Westhovens1 and
  2. Lieven Annemans2
  1. 1Department of Development and Regeneration, Skeletal Biology and Engineering Research Center KU Leuven, Rheumatology University Hospital Leuven, Leuven, Belgium
  2. 2Department of Public Health, I-CHER Interuniversity Centre for Health Economics Research, Ghent University, Ghent, Belgium
  1. Correspondence to Dr Rene Westhovens; rene.westhovens{at}uzleuven.be

Abstract

The cost of drugs is becoming an issue worldwide, in particular for inflammatory rheumatic diseases. In the current review, an overview of the scene is given with a specific emphasis on accessibility for those patients in real need of the available expensive treatments. The authors propose 7 principles for discussion that need to be addressed and are a responsibility for all stakeholders in rheumatology.

  • Arthritis
  • Economic Evaluations
  • Treatment

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.